Bisphosphonate therapy for the prevention of osteolysis in total joint replacements

Current Opinion in Orthopaedics

Volumn 9, Issue 6, 1998, Pages 81-87

  Shanbhag, Arun S ^a   Rubash, Harry E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

ARTICLE; ASEPTIC NECROSIS; BONE ATROPHY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; JOINT PROSTHESIS; LIFESPAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; TARGET CELL; TREATMENT OUTCOME;

EID: 0032457340     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-199812000-00014     Document Type: Article

References (60)

1. 1. National Institutes of Health: Total hip replacement: NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 1994:1-31.
2. 2. Friedman RJ, Black J, Galante JO, Jacobs JJ, Skinner HB: Current concepts in orthopaedic biomaterials and implant fixation. J Bone Joint Surg Am 1993, 75:1086-1109.
3. 3. Wright TM, Goodman SB: Implant Wear: The Future of Total Joint Replacement. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1996.
4. 4. Galante JO, Lemmons J, Spector M, Wilson PD Jr, Wright TM: The biologic effects of implant materials. J Orthop Res 1991, 9:760-775.
5. 5. Shanbhag AS, Rubash HE: Wear: the basis of particle disease in total hip arthroplasty. Techniques Orthop 1994, 8:269-274.
6. 6. Dowd JE, Schwendeman LJ, MacAulay W, Doyle JS, Shanbhag AS, Wilson S, Herndon JH, Rubash HE: Aseptic loosening in uncemented total hip arthroplasty in a canine model. Clin Orthop 1995, 319:106-121.
7. 7. Chiba J, Rubash HE, Kim KJ, Iwaki Y: The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop 1994, 300:304-312.
8. 8. Howie DW, Vernon-Roberts B, Oakeshott R, Manthey B: A rat model of resorption of bone at the cement-bone interface in the presence of polyethylene wear particles. J Bone Joint Surg Am 1988, 70:257-263.
9. 9. Shanbhag AS, Jacobs JJ, Glant TT, Gilbert JL, Black J, Galante JO: Composition and morphology of wear debris in failed uncemented total hip replacement arthroplasty. J Bone Joint Surg Br 1994, 76:60-67.
10. 10. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neill DA, Harris WH: The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 1983, 65:575-584.
11. 11. Kim KJ, Rubash HE, Wilson SC, D'Antonio JA, McClain EJ: A histological and biochemical comparison of the interface tissues in cementless and cemented hip prosthesis. Clin Orthop 1993, 287:142-152.
12. 12. Dorr LD, Bloebaum R, Emmanual J, Meldrum R: Histologic, biochemical and ion analysis of tissue and fluids retrieved during total hip arthroplasty. Clin Orthop 1990, 261:82-95.
13. 13. Goodman SB, Knoblich G, O'Connor M, Song Y, Huie P, Sibley R: Heterogeneity in cellular and cytokine profiles from multiple samples of tissue surrounding revised hip prostheses. J Biomed Mater Res 1996, 31:421-428.
14. 14. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT: Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasties. J Arthroplasty 1995, 10:498-506.
15. 15. Berger RA, Steel MJ, Schleiden M, Rubash HE: Preventing distal voids during cementation of the femoral component in total hip arthroplasty. J Arthroplasty 1993, 8:323-329.
16. 16. Harris WH, Davies JP: Modern use of modern cement for total hip replacement. Orthop Clin North Am 1988, 19:581 -589.
17. 17. Mulroy WF, Estok DM, Harris WH: Total hip arthroplasty with use of socalled second-generation cementing techniques. J Bone Joint Surg Am 1995, 77:1845-1852.
18. 18. Mulroy RD Jr, Harris WH: The effect of improved cementing techniques on component loosening in total hip replacement. J Bone Joint Surg Br 1990, 72:757-760.
19. 19. D'Antonio JA, Capello WN, Manley MT: Remodeling of bone around hydroxyapatite-coated femoral stems. J Bone Joint Surg Am 1996, 78:1226-1234.
20. 20. Jaffe WL, Scott DF: Total hip arthroplasty with hydroxyapatite-coated prostheses. J Bone Joint Surg Am 1996, 78:1918-1934.
21. 21. Dean JC, Tisdel CL, Goldberg VM, Parr J, Davy D, Stevenson S: Effects of hydroxyapatite tricalcium phosphate coating and intracancellous placement on bone ingrowth in titanium fibermetal implants. J Arthroplasty 1995, 10:830-838.
22. 22. Sumner DR, Turner TM, Purchio AF, Gombotz WR, Urban RM, Galante JO: Enhancement of bone ingrowth by transforming growth factor-b. J Bone Joint Surg Am 1995, 77:1135-1147.
23. 23. Riley EH, Lane JM, Urist MR, Lyons KM, Lieberman JR: Bone morphogenetic protein-2: biology and applications. Clin Orthop 1996, 324:39-46.
24. 24. Bragdon CR, O'Connor DO, Muratoglu OK, Jasty M, Ramamurti BS, Merrill E, Harris WH: A new polyethylene with undetectable wear at 12 million cycles [abstract]. Trans Soc Biomater 1998, 21:2.
25. 25. Shen F-W, McKellop HA, Salovey R: Improving the resistance to wear and oxidation of acetabular cups of UHMWPE by gamma radiation crosslinking and remelting [abstract]. Trans Soc Biomater 1998, 21:3.
26. 26. Spector M, Shortkroff S, Hsu H-P, Lane N, Sledge CB, Thornhill TS: Tissue changes around loose prostheses: a canine model to investigate the effects of an antiinflammatory agent. Clin Orthop 1990, 261:140-152.
27. 2 synthesis in the membrane surrounding particulate polymethylmethacrylate in the rabbit tibia. Clin Orthop 1991, 271:300-304.
28. 28. Wooley PH, Sud S, Robbins PD, Whalen JD, Evans CH: Contrasting effects of gene therapy to inhibit interleukin-1 β or tumor necrosis factor alpha in the murine inflammatory response to wear particles. Trans Orthop Res Soc 1998, 23:122-122.
29. 29. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443.
30. 30. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
31. 31. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994 79:1693-1700.
32. 32. Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97:2692-2696.
33. 33. Shanbhag AS, Hasselman CT, Rubash HE: Inhibition of wear debris-mediated osteolysis in a canine total hip arthroplasty (THA) model. Clin Orthop 1997, 344:33-43. This study is important for two reasons. First, the investigators used clinically relevant UHMWPE wear debris and developed osteolysis around uncemented total hip replacements in a canine model. Second, in another group of canines with similar hip replacements and introduction of wear debris, an oral treatment with bisphosphonates could inhibit localized periprosthetic bone loss.
34. 34. Horowitz SM, Algan SA, Purdon MA: Pharmacologic inhibition of particulate-induced bone resorption. J Biomed Mater Res 1996, 31:91-96.
35. 35. Wang X, Shanbhag AS, Rubash HE, Agrawal CM: Short-term effects of bisphosphonates on the biomechanical properties of canine bone. J Biomed Mater Res 1998, in press.
36. 36. Goodship AE, Lawes TJ, Green J, Eldridge JD, Kenwright J: The use of bisphosphonates to inhibit mechanically related bone loss in aseptic loosening of hip prostheses [abstract]. Trans Orthop Res Soc 1998, 23:2. In this study the investigators demonstrated that bisphosphonates also have the potential to reduce bone loss associated with stress shielding around metal implants.
37. 37. Lyons AR, Owen JE, Freedholm DA, Miller CG, Fasano G, Pye D, et al.: Effect of alendronate on periprosthetic bone mass [abstract]. Transactions of the 10th Combined Meeting of the Orthopaedic Association of the English Speaking World, Auckland, New Zealand; 1998:209. In this report the investigators have demonstrated that in patients with total hip replacements, oral therapy with bisphosphonates has the potential to increase the bone mineral density.
38. 38. Astrand J, Aspenberg P: Alendronate does not inhibit instability-induced bone resorption [abstract]. Trans Orthop Res Soc 1998, 23:28.
39. 39. Horowitz SM, Gonzales JB: Effects of polyethylene on macrophages. J Biomed Mater Res 1997, 15:50-56.
40. 40. Glant TT, Jacobs JJ: Response of three murine macrophage populations to particulate debris: bone resorption in organ cultures. J Orthop Res 1994, 12:720-731.
41. 41. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT: Effects of particles on fibroblast proliferation and bone resorption in vitro. Clin Orthop 1997, 342:205-217.
42. 42. Jingushi S, Yasuda K, Sakai H, Azuma Y, Ohta T, Iwamoto Y: Alendronate prevents bone resorption by isolated cells from periprosthetic granulation tissue in hips of revision total hip arthroplasty [abstract]. Trans Orthop Res Soc 1998, 23:1.
43. 43. Ritchie CK, Patel MA, Stamos BD, Horowitz SM: Alendronate reduces particle-induced cytokine production in macrophages [abstract]. Trans Orthop Res Soc 1998, 23:357.
44. 44. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
45. 1gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12:1358-1367. The studies to date had suggested that the primary action of bisphosphonates was on the osteoclasts, with minimal effect on the other cells such as the osteoblasts and macrophages. In this study the investigators demonstrated that clodronate, a first-generation bisphosphonate, can be toxic to macrophages. This effect was specific to individual drug formulations, and alendronate had no deleterious effect.
46. 46. Fleisch H, Russel RGG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969, 10:1262-1264.
47. 47. Russel RGG, Kislig A-M, Casey PA, Fleisch H, Thornton J, Schenk R, Williams DA: Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone. Calcif Tissue Res 1973, 11:179-195.
48. 48. Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts and bone. Calcif Tissue Int 1991, 49:407-415.
49. 49. Sato M, Grasser W, Endo N, Akins R, Simmons H: Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
50. 50. Fleisch H: Bisphosphonates in Bone Disease, edn 2. New York: Parthenon Publishing Group; 1995.
51. 51. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M: Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235-245.
52. 52. Sato M, Grasser W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990, 5:31-39.
53. 53. Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleisch H: The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calc Tissue Res 1972, 10:302-313.
54. 54. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al.: A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995, 17:137-144.
55. 55. Zimolo Z, Wesolowski G, Rodan GA: Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995, 96:2277-2283.
56. 56. Tanzi MC, Sket I, Gatti AM, Monari E: Physical characterization of acrytic bone cement cured with new accelerator systems. Clin Mater 1991, 8:131-136.
57. 57. Felix R, Guenther HL, Fleisch H: The subcellular distribution of [14C]dichloromethylene bisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 1984, 36:108-113.
58. 58. Ott SM: Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res 1993, 8(suppl):S597-S606.
59. 59. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993, 91:2004-2011.
60. 60. Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6:1003-1011.